Shares of Keymed Biosciences (HKEX: 02162) are soaring 5.17% in Thursday's trading session, following the release of the company's impressive 2024 annual results and pipeline updates. The biotechnology firm's stock price surge reflects investor optimism about its strong product performance and advancement in clinical trials across multiple therapeutic areas.
A key highlight from the annual report is the successful launch and sales performance of Stapokibart (CM310), an IL-4Rα antibody. The drug, approved for multiple indications including atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and seasonal allergic rhinitis, generated approximately RMB40 million in revenue within just three and a half months of its launch. This rapid market penetration demonstrates the drug's strong commercial potential and addresses significant unmet medical needs.
Keymed Biosciences also reported substantial progress across its diverse pipeline. Notably, the company's partnered Claudin 18.2 ADC (CMG901/AZD0901) with AstraZeneca is advancing in multiple clinical trials for various cancer indications. Additionally, other pipeline candidates such as CM313 (CD38 antibody), CM512 (TSLP x IL-13 bispecific antibody), and CM336 (BCMAxCD3 bispecific antibody) have shown promising results in their respective clinical studies. The company's focus on innovative therapies in oncology, immunology, and neurology has clearly resonated with investors, contributing to the stock's upward momentum.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。